Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pharma partnership

Biogen Idec building

Biogen cuts workforce and culls pipeline projects

Attempts to make major cost savings as MS drug sales slow

- PMLiVE

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

Roche Basel Switzerland

Roche’s investigational drug first to show efficacy in MS

Ocrelizumab shows positive results in large phase III study

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

- PMLiVE

Brandicourt steers Sanofi onto a new heading

Unveilsmajor restructuring of the French pharma group

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

- PMLiVE

Genzyme and Ablynx collaborate on multiple sclerosis research

Companies will investigate Nanobodies against MS target

Eli Lilly HQ

Lilly and Sanford-Burnham reveal immunology collaboration

Will aim to discover and develop therapies in the field

- PMLiVE

AZ and Sutter Health enter cardiometabolic collaboration

Three-year partnership will design and pilot new treatments

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links